Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

425
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
425
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.0K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.0K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

370
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
370
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.0K
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.01:25

Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.

3.4K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.4K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of cancer and mortality in patients with interstitial lung diseases: Danish cohort study.

The European respiratory journal·2026
Same author

Co-designing a Palliative Care Referral Tool for Patients with Fibrosing Interstitial Lung Disease.

Annals of the American Thoracic Society·2026
Same author

Risk and outcome of interstitial lung disease in inflammatory bowel disease: evidence from a Danish nationwide population-based cohort study.

Journal of Crohn's & colitis·2026
Same author

Olive Oil and the Impact of Gastrointestinal Adverse Events During Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: A Post-hoc Analysis of the MADIET Trial.

Archivos de bronconeumologia·2026
Same author

Lung disease in rheumatoid arthritis.

Nature reviews. Rheumatology·2026
Same author

Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.

Diagnostics (Basel, Switzerland)·2026
Same journal

Clinical remission in elderly patients with sarcoidosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

A case of a rapidly progressing, recurrent orbital mass.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Composite Inflammatory Indices for the Differentiation of Tuberculosis, Sarcoidosis, and Reactive Lymphadenopathy in Patients Undergoing EBUS-TBNA.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Supervised Home-Based Telerehabilitation for Idiopathic Pulmonary Fibrosis: A Pragmatic Service Evaluation in Routine Care with Detraining Follow-up.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Transcriptomic profiling of collagen gene expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same journal

Unveiling novel susceptibility genes for sarcoidosis by a cross-tissue transcriptome-wide association study.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
See all related articles

Related Experiment Video

Updated: Dec 20, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K

Erectile dysfunction is a common problem in interstitial lung diseases.

Andreas Fløe1, Ole Hilberg1, Marlies Wijsenbeek2

  • 1Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark.

Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG
|June 2, 2020
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) is common in men with interstitial lung disease (ILD), affecting over 70%. This condition is linked to reduced walking ability and older age, yet treatment is infrequent.

Keywords:
erectile dysfunctioninterstitial lung diseaserespiratory diseases

More Related Videos

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
05:56

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit

Published on: September 6, 2024

5.7K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

654

Related Experiment Videos

Last Updated: Dec 20, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

20.7K
Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit
05:56

Monitoring Lung Function with Electrical Impedance Tomography in the Intensive Care Unit

Published on: September 6, 2024

5.7K
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

654

Area of Science:

  • Pulmonology
  • Urology
  • Cardiovascular Health

Background:

  • Erectile dysfunction (ED) is a known complication of chronic diseases, potentially linked to hypoxia seen in interstitial lung disease (ILD).
  • Understanding the prevalence and risk factors of ED in ILD patients is crucial for comprehensive care.

Purpose of the Study:

  • To investigate the relationship between interstitial lung disease (ILD) and erectile dysfunction (ED) in male patients.
  • To identify factors associated with ED in this population.

Main Methods:

  • Prospective enrollment of male ILD patients diagnosed via HR-CT and/or biopsy across two European centers.
  • Assessment of ED using the International Index of Erectile Function questionnaire.
  • Collection of ILD type, lung function, 6-minute walking test (6MWT) distance, comorbidities, and smoking history data.

Main Results:

  • Of 54 participants, 70.4% reported some degree of ED, with 43.4% experiencing severe ED.
  • Older age and reduced 6MWT distance were significantly associated with moderate to severe ED.
  • Low diffusion capacity and higher BMI showed a trend towards increased ED risk.

Conclusions:

  • Severe ED is highly prevalent in men with ILD, correlating with poorer physical function and advanced age.
  • Current treatment rates for ED in ILD patients are low, indicating a need for increased clinical attention.
  • Physicians should routinely screen for and address ED as part of ILD patient management.